Our Leadership Team
Cancer52 benefits hugely from the expertise and skills of those individuals who give their time to help drive forward the agenda for rare and less common cancers. All are strong, senior and experienced individuals at board and strategy level, established and credible in their own right.
The board of directors was initially established in early 2012 alongside the creation of the organisation’s status as a not for profit company limited by guarantee. Board membership has been updated since and continues to represent a vibrant and experienced group of people committed to the aims of Cancer52.
Baroness Morgan of Drefelin (Previously Chief Executive of Breast Cancer Now) sits at the helm of the
organisation as honorary president, giving Cancer52 both a route through to the seat of government, as well as guidance on the lessons to be learnt from the bigger cancer organisations.
The board is responsible for shaping the direction of Cancer52 and is lead by its Chair, Anne MacDowell, supported by Vice-Chair, Rebecca Porta.
Honorary President Cancer52
Baroness Delyth
Morgan
Chair, Cancer52
Anne MacDowell
CEO, Cancer52
Chris
Walden
CEO, AMMF The Cholangiocarcinoma Charity
Helen Morement
CEO, The Urology Foundation
Rebecca Porta, Vice-Chair
Cancer52 Advisory Board MemberCancer Consultant
Dr Tom RoquesMRCP FRCR
Doctor
Dr Max Brodermann
Retired Financial Consultant
Michael Draeger
Research Assistant
Sophie Davies
